Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma
Open Access
- 11 April 2025
- journal article
- research article
- Published by Springer Nature in Apoptosis
- Vol. 30 (5-6) , 1482-1501
Abstract
Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) is the most common extra-nodal DLBCL. Metabolism-related factors have been associated with tumor progression, but the relationship between abnormal metabolism and prognosis of PGI-DLBCL remains unelucidated. In our study, consensus clustering based on metabolism-related genes classified PGI-DLBCL patients into two metabolic subtypes, and poor prognosis was associated with immunosuppressive microenvironment. A prognostic signature based on five metabolism-related genes (APOE, ALDH6 A1, PLOD2, IKBKB and ALDH1B1) was developed. Patients in high-risk group had a worse prognosis, with an immunosuppressive microenvironment. Moreover, 159 PGI-DLBCL patients were enrolled and divided into training cohort (n = 87) and validation cohort (n = 72). Univariate and multivariate Cox regression analysis showed metabolism-related factors were independent prognostic factors in PGI-DLBCL. A novel model (A-IPI score) combining APOA and NCCN-IPI was developed, and A-IPI score was better than NCCN-IPI score in predicting the prognosis of PGI-DLBCL patients. Furthermore, immunohistochemistry showed that ALDH1B1 was highly expressed in PGI-DLBCL and patients with high ALDH1B1 expression displayed worse prognosis. Moreover, cell proliferation assay revealed that the treatment with IGUANA-1, ALDH1B1 inhibitor, suppressed cell proliferation in DLBCL and IGUANA-1 exerted synergistic anti-tumor effects with PI3K inhibitor duvelisib. Additionally, we found that immune scores, ESTIMATE scores, and stromal scores were higher and the immune checkpoints (CTLA-4, PD-1, PD-L1) were down-regulated in patients with high ALDH1B1 expression. Collectively, our study constructed a novel metabolism-related prognostic model and highlighted the potential of metabolism-related gene ALDH1B1 as prognostic biomarker and drug target in PGI-DLBCL, providing new insights for the development of precision therapies in PGI-DLBCL patients.Keywords
Funding Information
- Shandong Provincial Natural Science Foundation (No.ZR2023MH376, No. ZR2023QH193)
- National Natural Science Foundation (No.82400231, No.82270200, No.82070203,No.81770210)
- China Postdoctoral Science Foundation (No. 2023M741506)
- Taishan Scholars Program of Shandong Province
- Shandong Provincial Engineering Research Center of Lymphoma
- Key Research and Development Program of Shandong Province (No.2018CXGC1213)
- Academic promotion programme of Shandong First Medical University (No. 2019QL018)
- Translational research grant of NCRCH (No.2021WWB02, No.2020ZKMB01)
This publication has 69 references indexed in Scilit:
- Aldehyde dehydrogenases and cell proliferationFree Radical Biology and Medicine, 2012
- IKKβ and NF-κB Transcription Govern Lymphoma Cell Survival through AKT-Induced Plasma Membrane Trafficking of GLUT1Cancer Research, 2011
- The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and ProliferationCell Metabolism, 2008
- Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseJournal of Clinical Investigation, 2007
- Primary diffuse large B-cell lymphoma of the stomachCritical Reviews in Oncology/Hematology, 2007
- Colorectal LymphomaClinics in Colon and Rectal Surgery, 2006
- Paris staging system for primary gastrointestinal lymphomasGut, 2003
- Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphomaAnnals of Oncology, 1999
- Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hostsInternational Journal of Cancer, 1996
- Lymphomas of the gastrointestinal tract.A study of 117 cases presenting with gastrointestinal diseaseCancer, 1978